You don’t have permission to access “http://www.war.gov/News/Releases/Release/Article/4371320/department-of-war-establishes-new-acquisition-model-to-more-than-triple-pac-3-m/” on this server.
Reference #18.13d91102.1767704373.448efee2
https://errors.edgesuite.net/18.13d91102.1767704373.448efee2
We are pleased to announce the appointment of two new partners and six new of counsel across the firm in Employment, Corporate and M&A, Technology and Innovation, Real Estate, Financial Regulation and Litigation, Dispute Resolution and Investigations.
These appointments reflect our commitment to investing in exceptional talent and strengthening the breadth of expertise across the firm. By promoting and developing our people, we can ensure that our clients benefit from innovative thinking, deep sector knowledge, and the highest standards of legal service.
Geoff Moore, Managing Partner, commented: “These appointments demonstrate the depth of expertise within our firm and our focus on supporting clients with the highest standards of legal advice, particularly in areas of key strategic importance. Each of these individuals brings outstanding experience and insight, and I am proud to see them take on these new roles as the firm continues to grow.”
Sarah advises on all aspects of employment law, including disciplinary investigations, contract terminations, recruitment, redundancies, settlement agreements, and discrimination complaints. She represents clients before the Workplace Relations Commission and Labour Court in disputes such as unfair dismissal, equality, transfer of undertakings, and working time. Sarah also acts for clients in employment-related civil court proceedings and advises on the employment aspects of commercial transactions and outsourcings, particularly TUPE compliance. She is a CEDR Accredited Mediator.
Sarah advises Irish and multinational public and private companies on all aspects of corporate and commercial law. She advises on domestic and cross-border mergers and acquisitions, corporate finance transactions, corporate reorganisations, corporate governance, and commercial contracts across a range of industries and sectors. Sarah also advises international and domestic publicly listed clients on strategic transactions such as public takeovers, capital raises, corporate restructuring, and governance matters.
Ciara has particular expertise in data protection, outsourcing, digital transformation, IT contracts, freedom of information, and export control. She works with financial institutions, corporates, and technology companies on a range of complex transformation and procurement projects, including cloud outsourcings, digital transformation projects, and business-critical IT contracts. She also advises a range of clients on data protection, including in relation to complex international data transfer strategies, such as binding corporate rules (BCRs).
Lisa specialises in securities law and governance for public companies with equity listings across multiple jurisdictions. As a key advisor in our PLC Advisory and Governance Group, she guides companies on compliance frameworks including market abuse regulations, shareholder engagement, and board governance to help them meet market and investor expectations. Lisa has extensive experience advising on equity capital markets transactions, including complex regulatory frameworks for initial listings and market transitions.
Elaine advises clients on commercial real estate transactions across all sectors, including office, retail, healthcare, logistics, hospitality and PRS/BTR. She has extensive experience in portfolio and single-asset acquisitions and disposals, landlord and tenant matters and asset management. She also regularly advises on the real estate aspects of property finance and corporate (M&A) transactions.
Kim advises domestic and international clients on all aspects of financial services regulation. Her clients include banks, investment firms, payment services firms, and e-money institutions offering services such as deposit taking, lending, investment, fintech, crypto-assets, and payment services. Kim provides guidance on Irish and EU authorisation, including applications for regulatory permissions. She advises on compliance, conduct of business, regulatory capital, market abuse, AML and countering the financing of terrorism. Kim has extensive experience in advising on consumer protection matters and also advises on financial services M&A matters.
Niamh works with Irish and international clients on all aspects of corporate law and governance, with a focus on public and private mergers and acquisitions, equity capital market transactions, corporate reorganisations, joint ventures, and general corporate advisory work. Niamh advises on Irish and multi-jurisdictional transactions across a broad range of industries and has considerable experience in public corporate governance and securities advisory work for publicly listed clients.
Zac advises on complex contractual disputes, shareholder disputes, and commercial property disputes, working with Irish and international corporates, investment funds, financial institutions, insolvency practitioners, and high-net-worth individuals. He has acted in arbitrations and in litigation matters at all levels of jurisdiction of the Irish courts. Zac is also experienced in pre-dispute risk management, negotiation, and mediation.
Standing, left to right: Ciara Anderson, Zac Van Horn, Sarah Faulkner, Elaine Caulfield, Lisa Boyle, Geoff Moore, Kim O’Dowd.
Sitting, left to right: Sarah McDermott, Niamh O’Toole.
Harsh Chugh will take on an expanded role as Global Head of Practices, Corporate Development and Administration. In this new role, he will lead Kyndryl’s Global Practices, effective immediately, and will lead Corporate Development beginning May 1. Country practices will continue to operate with the same reporting structure as they do today. Chugh will integrate the practices and corporate development agenda for future growth with a focus on leveraging the combined and holistic value the practices provide customers, while maintaining a flat structure. As Kyndryl’s Chief Operating Officer, Chugh has transformed the company through the successful transition services agreement (TSA) exit and solved tough commercial challenges. Chugh will continue to own all aspects of operations for Kyndryl.
Farhaz Thobani will become Chief Administrative Officer, responsible for Kyndryl’s operations, real estate, quote to cash and procurement, effective immediately. As President of Kyndryl Canada, Thobani transformed Kyndryl’s Canadian business while fostering a highly engaged team. Under his leadership, the team has strengthened customer relationships, elevated Kyndryl’s brand presence and laid a robust foundation for sustained growth in Canada.
Paul Savill will become, effective immediately, Global Practice Leader, Cyber Security and Resiliency, Network and Edge, which is a newly combined Global Practice that reflects the integrated way customers view and purchase network and security offerings. Previously, as Global Practice Leader for Network and Edge, Paul has been a senior leader at Kyndryl since it became an independent company and has transformed the Network and Edge Practice to focus on growth and innovation while building a strong, experienced team. He will bring together these two teams of experts to provide customers with a unified set of capabilities and support.
Ivan Dopplé has decided to retire following a distinguished career at Kyndryl. After building and leading Kyndryl operations during its transition to an independent company, Dopplé has led its Digital Workplace Services (DWS) Global Practice. Dopplé has been instrumental in establishing Kyndryl’s eminence in the DWS space, driven by a deep passion for customers and keen industry insights. Dopplé has also been an advocate for the company’s culture, including his leadership as the Executive Sponsor for KIN True Ability. He will remain at Kyndryl until July to transition with his successor and work on projects focused on advancing the company’s growth.
Michael Przytula will join Kyndryl on January 19 as Global Practice Leader, Digital Workplace. Przytula brings almost 30 years of experience leading and delivering Digital Workplace and Service Desk services for global customers at Accenture, Dell and HP. He has spent his career in this space, working across every role in the practice and brings a global perspective shaped by living and working in Australia, Asia and the United States.
SAN ANTONIO – Whataburger is giving you more to love in 2026 with a new Whatadeal menu.
You can enjoy options for as low as $3 for a limited time only at participating locations, according to a press release from the popular chain.
The new menu includes three options, with the ability to add small fries and a small drink for $2.49.
“We’ve always believed that good, fresh food should be easy to enjoy and easy on the wallet,” said Whataburger Senior Vice President and CMO Scott Hudler. “The Whatadeal menu is our way of giving fans more of what they love at prices that make it easy to come hungry and leave full.”
You can get a Big Ranch Wrap for $3. Whataburger said this is its Whatachick’n Strip with fresh veggies, ranch and American cheese wrapped in a tortilla.
For $4, you can chow down on a five-count Whatachick’n Bites. Just like it sounds, these are bite-sized crispy chicken pieces for dipping and snacking.
The Bacon and Cheese Whataburger Jr. is available for $5. The chain said this features a 100% beef patty topped with bacon and melty cheese.
You can learn more on Whataburger’s website.
Read more on KSAT:
Copyright 2026 by KSAT – All rights reserved.
Capecchi, M. R. Altering the genome by homologous recombination. Science 244, 1288–1292 (1989).
Google Scholar
Gowen, L. C., Johnson, B. L., Latour, A. M., Sulik, K. K. & Koller, B. H. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat. Genet. 12, 191–194 (1996).
Google Scholar
Hakem, R. et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85, 1009–1023 (1996).
Google Scholar
Liu, C. Y., Flesken-Nikitin, A., Li, S., Zeng, Y. & Lee, W. H. Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev. 10, 1835–1843 (1996).
Google Scholar
Ludwig, T., Chapman, D. L., Papaioannou, V. E. & Efstratiadis, A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 11, 1226–1241 (1997).
Google Scholar
Sharan, S. K. et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386, 804–810 (1997).
Google Scholar
Suzuki, A. et al. Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev. 11, 1242–1252 (1997).
Google Scholar
Shen, S. X. et al. A targeted disruption of the murine Brca1 gene causes γ-irradiation hypersensitivity and genetic instability. Oncogene 17, 3115–3124 (1998).
Google Scholar
Xu, X. et al. Centrosome amplification and a defective G2–M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3, 389–395 (1999).
Google Scholar
Connor, F. et al. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat. Genet. 17, 423–430 (1997).
Google Scholar
Patel, K. J. et al. Involvement of Brca2 in DNA repair. Mol. Cell 1, 347–357 (1998).
Google Scholar
Tutt, A. et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J. 20, 4704–4716 (2001).
Google Scholar
Lomonosov, M., Anand, S., Sangrithi, M., Davies, R. & Venkitaraman, A. R. Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. Genes Dev. 17, 3017–3022 (2003).
Google Scholar
Schlacher, K. et al. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 145, 529–542 (2011).
Google Scholar
Schlacher, K., Wu, H. & Jasin, M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51–BRCA1/2. Cancer Cell 22, 106–116 (2012).
Google Scholar
Hatchi, E. et al. BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. Mol. Cell 57, 636–647 (2015).
Google Scholar
Shivji, M. K. K., Renaudin, X., Williams, C. H. & Venkitaraman, A. R. BRCA2 regulates transcription elongation by RNA polymerase II to prevent R-loop accumulation. Cell Rep. 22, 1031–1039 (2018).
Google Scholar
Zhang, X. et al. Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis. Nat. Commun. 8, 15908 (2017).
Google Scholar
Patel, P. S. et al. RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors. J. Clin. Invest. 131, e140105 (2021).
Google Scholar
Xu, X., Aprelikova, O., Moens, P., Deng, C.-X. & Furth, P. A. Impaired meiotic DNA-damage repair and lack of crossing-over during spermatogenesis in BRCA1 full-length isoform deficient mice. Development 130, 2001–2012 (2003).
Google Scholar
Broering, T. J. et al. BRCA1 establishes DNA damage signaling and pericentric heterochromatin of the X chromosome in male meiosis. J. Cell Biol. 205, 663–675 (2014).
Google Scholar
Sharan, S. K. et al. BRCA2 deficiency in mice leads to meiotic impairment and infertility. Development 131, 131–142 (2004).
Google Scholar
Hakem, R., de la Pompa, J. L., Elia, A., Potter, J. & Mak, T. W. Partial rescue of Brca15–6 early embryonic lethality by p53 or p21 null mutation. Nat. Genet. 16, 298–302 (1997).
Google Scholar
Xu, X. et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat. Genet. 28, 266–271 (2001).
Google Scholar
Cao, L. et al. ATM–Chk2–p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency. EMBO J. 25, 2167–2177 (2006).
Google Scholar
Cao, L. et al. A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol. Cell 35, 534–541 (2009).
Google Scholar
Bouwman, P. et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17, 688–695 (2010).
Google Scholar
Bunting, S. F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243–254 (2010).
Google Scholar
Petrucelli, N., Daly, M. B. & Pal, T. In GeneReviews (eds Adam, M. P. et al.) (University of Washington, 1998–2025).
Ludwig, T., Fisher, P., Ganesan, S. & Efstratiadis, A. Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes Dev. 15, 1188–1193 (2001).
Google Scholar
Bachelier, R. et al. Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice. Oncogene 22, 528–537 (2003).
Google Scholar
Kim, S. S. et al. Hyperplasia and spontaneous tumor development in the gynecologic system in mice lacking the BRCA1-Δ11 isoform. Mol. Cell. Biol. 26, 6983–6992 (2006).
Google Scholar
Friedman, L. S. et al. Thymic lymphomas in mice with a truncating mutation in Brca2. Cancer Res. 58, 1338–1343 (1998).
Google Scholar
McAllister, K. A. et al. Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. Cancer Res. 62, 990–994 (2002).
Google Scholar
Xu, X. et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat. Genet. 22, 37–43 (1999).
Google Scholar
Liu, X. et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl Acad. Sci. USA 104, 12111–12116 (2007).
Google Scholar
McCarthy, A. et al. A mouse model of basal-like breast carcinoma with metaplastic elements. J. Pathol. 211, 389–398 (2007).
Google Scholar
Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418–425 (2001).
Google Scholar
Ludwig, T., Fisher, P., Murty, V. & Efstratiadis, A. Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice. Oncogene 20, 3937–3948 (2001).
Google Scholar
Szabova, L. et al. Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res. 72, 4141–4153 (2012).
Google Scholar
Perets, R. et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24, 751–765 (2013).
Google Scholar
Levanon, K., Crum, C. & Drapkin, R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol. 26, 5284–5293 (2008).
Google Scholar
Iyer, S. et al. Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy. Cancer Discov. 11, 384–407 (2021).
Google Scholar
Skoulidis, F. et al. Germline Brca2 heterozygosity promotes KrasG12D-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 18, 499–509 (2010).
Google Scholar
Rowley, M. et al. Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology 140, 1303–1313 (2011).
Google Scholar
Shakya, R. et al. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science 334, 525–528 (2011).
Google Scholar
Drost, R. et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 20, 797–809 (2011).
Google Scholar
Drost, R. et al. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. J. Clin. Invest. 126, 2903–2918 (2016).
Google Scholar
Chen, J. et al. 53BP1 loss rescues embryonic lethality but not genomic instability of BRCA1 total knockout mice. Cell Death Differ. 27, 2552–2567 (2020).
Google Scholar
Nacson, J. et al. BRCA1 mutational complementation induces synthetic viability. Mol. Cell 78, 951–959 (2020).
Google Scholar
Park, D. et al. Ablation of the Brca1–Palb2 interaction phenocopies Fanconi anemia in mice. Cancer Res. 80, 4172–4184 (2020).
Google Scholar
Pulver, E. M. et al. A BRCA1 coiled-coil domain variant disrupting PALB2 interaction promotes the development of mammary tumors and confers a targetable defect in homologous recombination repair. Cancer Res. 81, 6171–6182 (2021).
Google Scholar
Krais, J. J. et al. RNF168-mediated localization of BARD1 recruits the BRCA1–PALB2 complex to DNA damage. Nat. Commun. 12, 5016 (2021).
Google Scholar
Hartford, S. A. et al. Interaction with PALB2 is essential for maintenance of genomic integrity by BRCA2. PLoS Genet. 12, e1006236 (2016).
Google Scholar
Lim, P. X., Zaman, M., Feng, W. & Jasin, M. BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair. Mol. Cell 84, 447–462 (2024).
Google Scholar
Atanassov, B. S., Barrett, J. C. & Davis, B. J. Homozygous germ line mutation in exon 27 of murine Brca2 disrupts the Fancd2–Brca2 pathway in the homologous recombination-mediated DNA interstrand cross-links’ repair but does not affect meiosis. Genes Chromosomes Cancer 44, 429–437 (2005).
Google Scholar
Pathania, S. et al. BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat. Commun. 5, 5496 (2014).
Google Scholar
Konishi, H. et al. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc. Natl Acad. Sci. USA 108, 17773–17778 (2011).
Google Scholar
Sedic, M. et al. Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence. Nat. Commun. 6, 7505 (2015).
Google Scholar
Zong, D. et al. BRCA1 haploinsufficiency is masked by RNF168-mediated chromatin ubiquitylation. Mol. Cell 73, 1267–1281 (2019).
Google Scholar
Li, C. M. et al. Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer. Nat. Genet. 56, 2763–2775 (2024).
Google Scholar
Kumar, P. et al. Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution. PLoS Genet. 8, e1003027 (2012).
Google Scholar
Annunziato, S. et al. Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer. Nat. Commun. 10, 397 (2019).
Google Scholar
Liu, H. et al. Identifying and targeting sporadic oncogenic genetic aberrations in mouse models of triple-negative breast cancer. Cancer Discov. 8, 354–369 (2018).
Google Scholar
Menghi, F. et al. The tandem duplicator phenotype is a prevalent genome-wide cancer configuration driven by distinct gene mutations. Cancer Cell 34, 197–210 (2018).
Google Scholar
Molyneux, G. et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7, 403–417 (2010).
Google Scholar
Sau, A. et al. Persistent activation of NF-κB in BRCA1-deficient mammary progenitors drives aberrant proliferation and accumulation of DNA damage. Cell Stem Cell 19, 52–65 (2016).
Google Scholar
Bach, K. et al. Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors. Nat. Commun. 12, 1502 (2021).
Google Scholar
Ciwinska, M. et al. Mechanisms that clear mutations drive field cancerization in mammary tissue. Nature 633, 198–206 (2024).
Google Scholar
Rottenberg, S. et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl Acad. Sci. USA 104, 12117–12122 (2007).
Google Scholar
Zander, S. A. et al. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res. 70, 1700–1710 (2010).
Google Scholar
Pajic, M. et al. Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo. Cell Cycle 9, 3780–3791 (2010).
Google Scholar
Pajic, M. et al. Selected alkylating agents can overcome drug tolerance of G0-like tumor cells and eradicate BRCA1-deficient mammary tumors in mice. Clin. Cancer Res. 23, 7020–7033 (2017).
Google Scholar
Evers, B. et al. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin. Cancer Res. 16, 99–108 (2010).
Google Scholar
Planells-Cases, R. et al. Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs. EMBO J. 34, 2993–3008 (2015).
Google Scholar
Widmer, C. A. et al. Loss of the volume-regulated anion channel components LRRC8A and LRRC8D limits platinum drug efficacy. Cancer Res. Commun. 2, 1266–1281 (2022).
Google Scholar
Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105, 17079–17084 (2008).
Google Scholar
Hay, T. et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res. 69, 3850–3855 (2009).
Google Scholar
Jaspers, J. E. et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 3, 68–81 (2013).
Google Scholar
Xu, G. et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature 521, 541–544 (2015).
Google Scholar
Barazas, M. et al. The CST complex mediates end protection at double-strand breaks and promotes PARP inhibitor sensitivity in BRCA1-deficient cells. Cell Rep. 23, 2107–2118 (2018).
Google Scholar
Ter Brugge, P. et al. Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer. J. Natl Cancer Inst. 108, djw148 (2016).
Google Scholar
Gogola, E. et al. Selective Loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality. Cancer Cell 33, 1078–1093 (2018).
Google Scholar
Paes Dias, M. et al. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps. Mol. Cell 81, 4692–4708 (2021).
Google Scholar
Barazas, M. et al. Radiosensitivity is an acquired vulnerability of PARPi-resistant BRCA1-deficient tumors. Cancer Res. 79, 452–460 (2019).
Google Scholar
Juvekar, A. et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2, 1048–1063 (2012).
Google Scholar
Ding, L. et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 25, 2972–2980 (2018).
Google Scholar
Pantelidou, C. et al. PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 9, 722–737 (2019).
Google Scholar
Wang, Q. et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nat. Commun. 13, 3022 (2022).
Google Scholar
Zatreanu, D. et al. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nat. Commun. 12, 3636 (2021).
Google Scholar
Zhou, J. et al. A first-in-class polymerase θ inhibitor selectively targets homologous-recombination-deficient tumors. Nat. Cancer 2, 598–610 (2021).
Google Scholar
Mateos-Gomez, P. A. et al. Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination. Nature 518, 254–257 (2015).
Google Scholar
Ceccaldi, R. et al. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature 518, 258–262 (2015).
Google Scholar
Krais, J. J. et al. Genetic separation of Brca1 functions reveal mutation-dependent Polθ vulnerabilities. Nat. Commun. 14, 7714 (2023).
Google Scholar
DuPage, M. & Jacks, T. Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr. Opin. Immunol. 25, 192–199 (2013).
Google Scholar
Nolan, E. et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci. Transl. Med. 9, eaal4922 (2017).
Google Scholar
Rebbeck, T. R. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346, 1616–1622 (2002).
Google Scholar
Poole, A. J. et al. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314, 1467–1470 (2006).
Google Scholar
Nolan, E. et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat. Med. 22, 933–939 (2016).
Google Scholar
Sigl, V. et al. RANKL/RANK control Brca1 mutation-driven mammary tumors. Cell Res. 26, 761–774 (2016).
Google Scholar
van de Ven, M. et al. BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling. J. Pathol. 246, 41–53 (2018).
Google Scholar
Gorrini, C. et al. Estrogen controls the survival of BRCA1-deficient cells via a PI3K–NRF2-regulated pathway. Proc. Natl Acad. Sci. USA 111, 4472–4477 (2014).
Google Scholar
Vinayak, S. & Ford, J. M. PARP inhibitors for the treatment and prevention of breast cancer. Curr. Breast Cancer Rep. 2, 190–197 (2010).
Google Scholar
To, C. et al. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev. Res. 7, 698–707 (2014).
Google Scholar
van de Ven, M. et al. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice. J. Pathol. 241, 511–521 (2017).
Google Scholar
Zeng, J. et al. A genetic mosaic mouse model illuminates the pre-malignant progression of basal-like breast cancer. Dis. Model. Mech. 16, dmm050219 (2023).
Google Scholar
Singh, A. K. & Yu, X. Tissue-specific carcinogens as soil to seed BRCA1/2-mutant hereditary cancers. Trends Cancer 6, 559–568 (2020).
Google Scholar
Kass, E. M., Lim, P. X., Helgadottir, H. R., Moynahan, M. E. & Jasin, M. Robust homology-directed repair within mouse mammary tissue is not specifically affected by Brca2 mutation. Nat. Commun. 7, 13241 (2016).
Google Scholar
Uijttewaal, E. C. H. et al. CRISPR-StAR enables high-resolution genetic screening in complex in vivo models. Nat. Biotechnol. 43, 1848–1860 (2024).
Google Scholar
Yamashita, M. et al. Cell-type specific, inducible and acute degradation of targeted protein in mice by two degron systems. Nat. Commun. 15, 10129 (2024).
Google Scholar
Pettitt, S. J. et al. Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov. 10, 1475–1488 (2020).
Google Scholar
Billing, D. et al. The BRCT domains of the BRCA1 and BARD1 tumor suppressors differentially regulate homology-directed repair and stalled fork protection. Mol. Cell 72, 127–139 (2018).
Google Scholar
Stratton, M. R. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349, 1505–1510 (1997).
Google Scholar
Lakhani, S. R. et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl Cancer Inst. 90, 1138–1145 (1998).
Google Scholar
Bhin, J. et al. Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors. Cell Rep. 42, 112538 (2023).
Google Scholar
Holstege, H. et al. Cross-species comparison of aCGH data from mouse and human BRCA1– and BRCA2-mutated breast cancers. BMC Cancer 10, 455 (2010).
Google Scholar
During plant virus transmission by piercing-sucking insects, most viruses are inoculated into the plant phloem via the insect’s secreted saliva (Arcà and Ribeiro, 2018; Conway et al., 2016; Wu et al., 2022). Thus, insect saliva acts as an interface for the virus–insect–host tripartite interaction and can directly promote viral transmission to, and infection of, the host plants (Sun et al., 2020; Wu et al., 2022). However, despite the importance of insect salivary proteins in this tripartite interaction, there is still much to learn about how these proteins enable successful viral infection.
Previous studies have revealed that there are two ways in which insect saliva facilitates viral infection. One is an indirect approach whereby the saliva modulates the host microenvironment at the feeding site, and saliva effectors work together to allow the arthropod to go unnoticed while it feeds on the host plant (Acevedo et al., 2019; Arcà and Ribeiro, 2018; Sun et al., 2020). For example, our work indicated that a Laodelphax striatellus mucin protein, LssaMP, enables the formation of the salivary sheath and facilitates the transmission of rice stripe virus (RSV) into the rice phloem (Huo et al., 2022). The study on leafhoppers revealed that the expression of a saliva calcium-binding protein is inhibited by rice gall dwarf virus (RGDV), thus causing an increase of cytosolic Ca2+ levels in rice and triggering callose deposition and H2O2 production. This increases the frequency of insect probing, thereby enhancing viral horizontal transmission into the rice phloem (Wu et al., 2022). The other mechanism by insect saliva to facilitate virus infection is direct regulation, whereby saliva proteins promote virus transmission through specific molecular interactions (Wen et al., 2019). Direct saliva protein–pathogen interactions have been reported in animal pathogens. For example, during transmission of Borrelia burgdorferi by Ixodes scapularis, the saliva protein Salp15 of I. scapularis binds to the bacterial outer surface protein C, which prevents the bacterium from being recognized by the animal immune system. In this way, the saliva protein enables the pathogen to infect the animal host (Ramamoorthi et al., 2005; Schuijt et al., 2008). Although most plant viruses are heavily dependent on insect vectors for plant-to-plant transmission (Gray, 2008), the direct function of insect saliva proteins in mediating virus transmission remains largely uninvestigated.
During sap-feeding, arthropods produce two distinct types of saliva at different stages of the feeding process: gel saliva and watery saliva (Bonaventure, 2012; Lou et al., 2019). The former forms a salivary sheath to provide a smooth path for the stylet penetration (Lou et al., 2019). The latter is mainly secreted into the phloem sieve elements to prevent them from plugging up and suppress plant defense responses. Some salivary components may act as herbivore-associated molecular patterns that can trigger pattern-triggered immunity, and certain salivary effectors may be recognized by plant resistance proteins to induce effector-triggered immunity, etc. (Huang et al., 2017; Ji et al., 2017; Yi et al., 2021).
For phloem-feeding insects, callose deposited on phloem sieve plate and plasmodesmata of sieve elements functions as a defense mechanism by reducing insect feeding and preventing viral movement (Hao et al., 2008; Hipper et al., 2013; Will and Vilcinskas, 2015; Zavaliev et al., 2011; Yue et al., 2022). Callose is a β-(1,3)-D-glucan polysaccharide that is synthesized by callose synthases and degraded by β-(1,3)-glucanases. Plants defend themselves by depositing callose at the sieve plates and plasmodesmata in response to virus infection, whereas viruses counter this defense by activating β-(1,3)-glucanases to degrade callose (Bucher et al., 2001; Hao et al., 2008; Wu et al., 2022; Zavaliev et al., 2011).
RSV is the causative agent of rice stripe disease, a serious disease of rice crops that has occurred repeatedly in China, Japan, and Korea (Xu et al., 2021). RSV is completely dependent on insect vectors for transmission among its host plants, and L. striatellus is the main vector (Xu et al., 2021; Zhao et al., 2017). L. striatellus transmits RSV in a persistent-propagative manner. The virus initially infects the midgut, then disperses from the hemolymph into the salivary glands and is inoculated into the plant host during L. striatellus feeding (Huo et al., 2022). L. striatellus belongs to the order Hemiptera, whose members mainly feed from sieve tubes through their mouthparts (stylets) that penetrate plant tissues and reach sieve tubes to ingest the phloem sap (Tjallingii, 2006; van Bel and Will, 2016). RSV is mainly secreted into the rice phloem via the watery saliva (Huo et al., 2022; Wang and Blanc, 2021).
In this study, we identified a molecular interaction among RSV, an L. striatellus saliva protein, and a plant β-1,3-glucanase. The insect saliva protein directly binds to the RSV nucleocapsid protein (NP) and then binds to a rice thaumatin-like protein to activate its β-1,3-glucanase activity. The activation of β-1,3-glucanase helps RSV infection by inhibiting callose deposition in response to viral infection.
The European textile sector continues to operate on largely linear production models, with around 73 % of post-consumer textiles in the EU incinerated or landfilled. Transitioning to a system of durable, reusable, repairable, and recyclable textiles is therefore essential to reducing waste, emissions, and virgin resource dependency. This transition relies on high-quality product and material data. Traceability enables the tracking of fibres, processes, and actors across the supply chain, while transparency ensures that information is accessible to the relevant stakeholders. Reliable data underpin circular business models, support verification of environmental claims, and improve sorting, reuse, and recycling efficiency.
This PESCO-UP policy brief aims to contribute timely evidence to the ongoing debate on traceability and transparency in the textiles sector. This comes at a critical moment when the Delegated Act for Textiles under the Ecodesign for Sustainable Products Regulation (ESPR) is still under preparation. Once adopted, it will define compulsory data to be collected and shared, governance rules, and implementation timelines for the Digital Product Passport (DPP) in the textiles sector. As such, it is essential that the requirements reflect real needs and capacities of actors involved in textile sorting and recycling, while also taking potential challenges for these and other actors in the supply chain (including brands, software providers, manufacturers etc.) into account. Ensuring that the DPP is practical, relevant, and scalable will be crucial to unlocking circular business models in the sector and ultimately achieving the environmental and social outcomes the EU has set for the textile industry.
This policy brief was written in the context of the PESCO-UP project, funded by the European Union under grand agreement No. 101138367. This policy brief was first published on .
The European Bank for Reconstruction and Development (EBRD) is promoting further growth in domestic production of pharmaceutical products in Uzbekistan by supporting the operations of leading local manufacturer Nika Pharm.
Nika Pharm will use the EBRD loan of up to US$ 20 million to restructure its balance sheet and upgrade equipment and facilities in order to increase production capacity, improve product quality and bring the entire manufacturing process into compliance with the Good Manufacturing Practice (GMP) standards of the World Health Organisation’s certification scheme.
The company has been an EBRD client since 2021 and is a well-established producer of tablets, capsules, sachets and nasal sprays for use in the treatment of common colds, as well as in gastroenterology, paediatrics and urology. During this time, Nika Pharm has become a leader in several key segments, including decongestants, and has shown strong and sustainable growth by replacing imports with high-quality local production.
The project will help to expand Nika Pharm’s manufacturing base, improve its sustainability and efficiency, and lead to an average 140 per cent increase in the company’s production of generic pharmaceuticals and prescription drugs. Together with GMP certification, this will allow Nika Pharm to strengthen its position both domestically and regionally.
Uzbekistan’s rapidly growing pharmaceuticals market, which is set to expand by a further 10 per cent by 2029, is dominated (around 75 per cent) by imported medicines. The project will help contribute to the government’s plan of eventually bringing the share of locally produced pharmaceuticals to 80 per cent.
The EBRD has invested over US$ 6.6 billion in Uzbekistan to date through 196 projects, with the majority of those funds supporting private entrepreneurship, contributing to the country’s economic development.